Clovis Pops on Bristol-Myers Partnership; Intercept Dives on Weak Earnings: Biotech Movers

Clovis Pops on Bristol-Myers Partnership; Intercept Dives on Weak Earnings: Biotech Movers


Shares of Clovis Oncology Inc. were down 7.4% to $90.80 in premarket trading on Monday, July 31. The Boulder, Colo.-based firm and Bristol-Myers Squibb Co. unveiled a collaboration to evaluate the combination of Bristol-Myers' s immunotherapy Opdivo and Clovis Oncology's poly polymerase inhibitor Rubraca in Phase 3 studies in advanced advanced ovarian cancer and advanced triple-negative breast cancers.



from Biotech News